BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Decrease in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 921,900 shares, a decline of 16.2% from the November 15th total of 1,100,000 shares. Based on an average daily volume of 840,800 shares, the short-interest ratio is currently 1.1 days.

Institutional Investors Weigh In On BioLineRx

A number of large investors have recently made changes to their positions in BLRX. PVG Asset Management Corp bought a new stake in shares of BioLineRx in the 2nd quarter worth approximately $70,000. Atria Investments Inc lifted its stake in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC purchased a new position in shares of BioLineRx in the 2nd quarter valued at approximately $462,000. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Trading Up 0.0 %

BLRX traded up $0.00 on Monday, hitting $0.23. 119,128 shares of the company were exchanged, compared to its average volume of 492,448. The stock has a market capitalization of $17.99 million, a PE ratio of -1.02 and a beta of 1.39. BioLineRx has a 12 month low of $0.21 and a 12 month high of $1.70. The firm has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.57. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BLRX. HC Wainwright lowered their target price on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th. StockNews.com started coverage on BioLineRx in a research report on Tuesday, December 10th. They set a “hold” rating on the stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.